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Novel Plasmodium antigens 
identified via genome-based 
antibody screen induce protection 
associated with polyfunctional T 
cell responses
Sophie Schussek1,2, Angela Trieu1, Simon H. Apte  1, John Sidney3, Alessandro Sette3 & 
Denise L. Doolan1,4
The development of vaccines against complex intracellular pathogens, such as Plasmodium spp., 
where protection is likely mediated by cellular immune responses, has proven elusive. The availability 
of whole genome, proteome and transcriptome data has the potential to advance rational vaccine 
development but yet there are no licensed vaccines against malaria based on antigens identified from 
genomic data. Here, we show that the Plasmodium yoelii orthologs of four Plasmodium falciparum 
proteins identified by an antibody-based genome-wide screening strategy induce a high degree of 
sterile infection-blocking protection against sporozoite challenge in a stringent rodent malaria model. 
Protection increased in multi-antigen formulations. Importantly, protection was highly correlated with 
the induction of multifunctional triple-positive T cells expressing high amounts of IFN-γ, IL-2 and TNF. 
These data demonstrate that antigens identified by serological screening are targets of multifunctional 
cellular immune responses that correlate with protection. Our results provide experimental validation 
for the concept of rational vaccine design from genomic sequence data.
With almost half of the world’s population (an estimated 3.2 billion people) at risk of malaria, approximately 200 
million reported clinical cases and half a million deaths annually, mostly in children under the age of 5 years, 
malaria remains a major public health problem1. Due to the rapidly developing resistance of the Plasmodium par-
asites and Anopheles vectors to chemical interventions, vaccination against malaria is considered a public health 
priority. However, the complexity of the pathogen and of the immune response required to protect the human 
host from infection or severe disease has hindered vaccine development.
Plasmodium spp. parasites have a multi-stage lifecycle including an invertebrate and a vertebrate host and 
express ~5,300 proteins in a stage-specific manner2. The pre-erythrocytic stage of the parasite lifecycle represents 
an attractive target for vaccination, because inhibition of parasite growth in hepatocytes can reduce or complete 
ablate blood stage parasitemia, thus delaying or preventing clinical symptoms and disease pathology and sub-
sequent transmission. Indeed, infection with radiation attenuated Plasmodium spp. sporozoites (RAS), whose 
development is halted in the liver, can induce sterile protection against sporozoite challenge in rodent and human 
models3,4. Attenuation of parasites has been also achieved using reverse-genetic methods to generate genetically 
attenuated parasites (GAP) able to invade but only partially develop within the host5. However, these approaches 
require the generation of large numbers of sporozoites in mosquitoes and there is evidence of attenuated para-
sites reverting to their actively infective form6. The success of vaccination with P. falciparum RAS7 demonstrates 
the feasibility of inducing sterile infection-blocking protective immunity and suggests that antigens expressed 
by the liver stage parasite would be effective vaccine targets. However only a very small fraction (<0.5%) of the 
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Plasmodium spp. proteome has been evaluated for vaccine efficacy8 and antigens associated with solid sterile 
infection-blocking immunity have not been identified9. Indeed, failure to develop an effective malaria vaccine 
is likely due to the limited list of potential antigens thus far evaluated and their assessment predominantly as 
single-antigen based vaccines10,11.
The most advanced malaria vaccine candidate, RTS,S (also known as MosquirixTM), is based on the dominant 
sporozoite surface protein, P. falciparum circumsporozoite protein (CSP)12, and has been in development since 
the 1980s. Despite many decades of research and almost 50 clinical studies, the recent Phase 3 trial of RTS,S/
AS01 in Africa has been disappointing13. Vaccine efficacy against clinical malaria in the target group of infants 
aged 6–12 weeks at first vaccination was only 18% following the 3-dose primary schedule and 26% following a 
booster dose at 18 months, and decayed rapidly13,14. Of concern, this Phase 3 evaluation identified a risk of febrile 
seizures for RTS,S/AS01 as well as significantly more cases of both cerebral malaria and meningitis in vaccine 
recipients than controls and significantly higher all-cause mortality in girls13. Thus, although the RTS,S/AS01 vac-
cine received a positive scientific opinion from the European Medicines Agency for active immunization against 
malaria of children aged 6 weeks to 17 months15, the World Health Organization has not recommended RTS,S/
AS01 for routine use, pending resolution of a number of uncertainties related to vaccine impact and vaccine safety 
as well as programmatic aspects16.
In order to meet the public health need and the goals of the roadmap set by the malaria vaccine community17, 
one approach being advanced by a number of researchers and funding agencies is to enhance the efficacy of RTS,S 
by identifying novel antigens that work in synergy with CSP. Other well characterised P. falciparum sporozoite and 
liver antigens include sporozoite surface protein (SSP2/TRAP), liver stage antigen 1 (LSA1), cell-traversal protein 
for ookinetes and sporozoites (CelTOS), sporozoite threonine asparagine rich protein (STARP) and exported 
protein 1 (EXP1) but none of these have proved to be highly efficacious in clinical studies (reviewed in ref.8).
An alternative strategy is to specifically avoid building on RTS,S11. This is based on the premise that 
rational antigen selection is important and that antigens such as the CSP may be “red herrings” presented by 
the Plasmodium parasite to the human host to divert responses away from other potential targets of protective 
immune responses. This approach is enabled by recent advances in gene sequencing and high-throughput anal-
ysis which provide the foundation for mining whole genome and proteome datasets to identify potential vaccine 
candidates9,18. We have hypothesised that proteins identified from genome-based datasets using biologically rel-
evant criteria, such as association with protection, may be excellent vaccine targets9. In particular, we proposed 
that protein microarrays expressing the proteome of the pathogen of interest and probed with sera/plasma from 
exposed or immune individuals represent a promising platform to discover target antigens for vaccines and diag-
nostics9,18. In a previous study9, we probed a partial P. falciparum protein microarray with plasma from clinically 
divergent groups of individuals immunised with RAS, and identified 16 novel antigens strongly associated with 
sterile protective immunity (RAS ‘signature’ antigens). In another study19, we utilised the same protein microarray 
platform to screen plasma from children and young adults living in endemic areas of Mali and identified 46 pro-
teins associated with protection from disease during the malaria season (naturally acquired immunity ‘signature’ 
antigens).
In the work presented herein, we have build on our previous studies to investigate four antigens associated 
with protection in humans for their vaccine potential, in the virulent P. yoelii rodent malaria model. We evalu-
ated T cell and antibody responses as well as protection against sporozoite and blood-stage challenge induced 
by immunisation of BALB/c mice with the P. yoelii orthologues of these novel antigens, both individually and in 
combination, using DNA/protein and peptide/adjuvant regimens. The first strategy represents a whole-antigen 
immunisation strategy incorporating immunisation with antigen encoding plasmid DNA and recombinant pro-
tein in order to maximise immune responses to all possible epitopes; DNA/protein strategies have previously 
proved successful in inducing protection in animal models of malaria20. The peptide/adjuvant strategy, on the 
other hand, was designed to focus immune responses on putative CD4+ and CD8+ T cell epitopes predicted to 
bind BALB/c MHC class I and class II molecules with high affinity. We elected to formulate the pool of predicted 
peptide epitopes with the adjuvant AbISCO100, a commercially available ISCOM matrix formulation, previously 
described to generate a balanced immune response with both Th1 and Th2 characteristics21. We show that each 
of the four proteins is a target of protective immune responses and correlate protection with the induction of 
multifunctional Th1 T cell responses. We further show enhanced efficacy with multi-antigen combinations, and 
correlate vaccine-induced protection with the induction of multifunctional triple-positive T cells expressing high 
amounts of IFN-γ, IL-2 and TNF.
Results
Antigen selection & bioinformatic analysis. The selection of novel genome-derived antigens for eval-
uation in vivo was based on the results of two protein microarray studies. In one study, 16 pre-erythrocytic pro-
teins were associated with protection induced in human volunteers by immunisation with radiation attenuated 
P. falciparum sporozoites (RAS ‘signature’ antigens)22. Four of these 16 novel proteins (MAL13P1.22, PFI0925w, 
PFL1620w and PFE0060w) were also identified in another study as associated with protection against re-infection 
in individuals living in endemic areas in Mali (naturally acquired immunity ‘signature’ antigens)19 (Table 1). Thus, 
the four proteins each shared signatures implicated with protection induced by both experimental immunisation 
and natural infection. One of these, P. falciparum erythrocyte surface protein 2 (PIESP2; PFE0060w), does not 
have any known orthologues in rodent malaria species (Table 1). Antigen (PF14_0051) was also highly associated 
with protection in RAS immunised volunteers and reactive in protein microarray studies of multiple naturally 
exposed populations from different endemic regions.
The protein microarray used to identify these antigens was fabricated using a high-throughput cloning and 
protein expression system22–24. In that system, the size of target gene fragments is limited to approximately 3000 bp 
due to reduced PCR amplification efficiency23. Accordingly, large proteins were split into multiple segments for 
www.nature.com/scientificreports/
3Scientific RepoRtS | 7: 15053  | DOI:10.1038/s41598-017-15354-0
evaluation in the P. yoelii rodent model. Two of our four target antigens could be evaluated using the full-length 
orthologous genes (PY01533: 2481 bp, PY01606: 3000 bp), while the other two (PY03673: 4282 bp, PY03832: 
9161 bp) were split into antigenic segments corresponding to the P. falciparum sequence showing the highest 
reactivity on the protein microarrays (exon 1 segment 3 for PY03832; exons 2 and 4 for PY03673) (Table 1).
Mass spectrometry data for P. falciparum sporozoite and blood-stages showed expression of the four target 
antigens in sporozoites, as well as blood-stage merozoites or blood-stage trophozoites25 PlasmoDB; www.plas-
moDB.org). Proteomic and transcriptomic datasets of P. yoelii sporozoite and liver stages indicated that PY01533, 
P.y gene ID P.f ortholog
Product 
description













acquiredb Spz Mrz Tpz Gmt















5 10 0.2 0 0 0 no 0 0.016 34%, 4% exon 1 segment 3 9161 2000
PY03168 PF3D7_0304600 PFC0210c circumsporozoite protein 14 N/A 10.1 0 0 0 yes 1 0.055 33%, 45% full-length 1176 1176
Table 1. Characteristics of target antigens. a‘Signature antigens’ associated with protection after experimental 
vaccination with radiation-attenuated sporozoites (RAS)22. b‘Signature antigens’ associated with protection 
against severe malaria in children and young adults in Mali19. cMultidimensional protein identification 
technology to survey of sporozoite (Spz), merozoite (Mrz), trophozoite (Trp) and gametocyte (Gmt) 
proteome30. dSP, signal peptide; and TM, transmembrane regions of P. falciparum proteins, and P. yoelii 
orthologues, using SignalP28,29 and TMHMM227. eSingle nucleotide polymorphism (SPN) density calculated as 
number of total SNP over the gene length in bp (both derived from PlasmoDB; www.plasmodb.org). fBLASTP 
identity of target proteins to human proteome and query coverage87. gMost immunogenic P. falciparum open 








BLASTP P.y to mouse 
%identity, %coverage
Vaxijenb Algpredc TargetP1.1d
P.f P.b P.ch P.k P.v
antigen 
probability IgE epitope MAST SVM score ARPs
Subcellular 
location
PY01533 full-length 78.5 73.5 75 74.6 75.4 sporozoite, blood-stage schizont 50%, 82% 0.5072 VKGEEKEPSK
Non 
allergen 1.13 no hits n.d.
PY01606 full-length 64.3 66.1 63.9 67 62.7 sporozoite, blood-stage schizont 29%, 68% 0.5979 no
Non 
allergen 1.12 no hits n.d.
PY03673 full-length 48.7 51.1 53.5 56.2 47.4 salivary sporozoite, liver-stages 28%, 9% 0.4744 no
Non 
allergen 1.03 no hits mitochondrial
PY03673 exons 2+4 42.2 58.6 57.6 38.6 41.2
PY03832 full-length 32.6 44.3 28.6 26.3 24.6 liver stage 40h after infection 36%, 7% 0.6209 no
Non 
allergen 1.11 no hits n.d.
PY03832 exon 1 segment 3 61.5 92.1 84.7 38.9 47.6
PY03168 full-length 40.3 36.8 20.9 19.4 midgut sporozoite 49%, 28% 0.0558 no Non allergen 0.31 no hits n.d.
Table 2. Bioinformatic analysis of target antigens. aNucleotide ClustalW2.2 alignment of Py 17XNL sequences 
to other Plasmodium species: P. falciparum 3D7 (P.f), P. berghei ANKA (P.b), P. chabaudi chabaudi (P.ch), P. 
knowlesi strain H (P.k), P. vivax Sal-1 (P.v); data shown as alignment score reflecting % identity of aligned 
sequences; sequences and protein expression data derived from PlasmoDB (www.plasmodb.org). bAlignment-
free approach for antigen prediction, which is based on auto-cross covariance (ACC) transformation of protein 
sequences into uniform vectors of principal amino acid properties25. chttp://www.imtech.res.in/raghava/
algpred/; Prediction of allergens based on similarity of known epitopes with any region of protein, IgE epitope 
mapping, MEME/MAST allergen motifs, amino acid or dipeptide composition, BLAST search against 2890 
allergen-representative peptides (ARPs). dhttp://www.cbs.dtu.dk/services/TargetP/; Based on the predicted 
presence of any of the N-terminal presequences: chloroplast transit peptide (cTP), mitochondrial targeting 
peptide (mTP) or secretory pathway signal peptide (SP). n.d. = not determined.
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PY1606 and PY03673 are most highly expressed in salivary gland sporozoites and PY03832 in liver-stage parasite 
40 hr after infection (Table 2) (www.plasmoDB.org, ref.26).
None of our target P. falciparum antigens have predicted transmembrane elements, as evaluated using stand-
ard transmembrane prediction algorithms27. SignalP predicted a signal peptide sequence for MAL13P1.22 and 
PF14_0051, but not for PFI0925w and PFL1620w, suggesting possible secretion of those proteins28,29. A compar-
ison of single nucleotide polymorphisms (SNP) between different P. falciparum isolates showed low SNP density 
(≤0.03) for the selected antigens (Table 1) indicating all four target antigens are highly conserved between P. 
falciparum strains. Furthermore, these antigens show high conservation across Plasmodium species as evidenced 
by high percentage of homology (56% ± 15.4%) in a ClustalW alignment of orthologous nucleotide sequences 
(Table 2). Three of the four P. falciparum antigens (except PFI0925w) had low protein sequence identity to the 
human proteome, indicating a low propensity of induction of autoimmune reactivity (Table 1). Similarly, a 
sequence analysis between the P. yoelii orthologues and the mouse proteome revealed that PY01606 and PY03673 
had very low sequence identity to the host, while PY01533 and PY03832 were more conserved across pathogen 
and host species (Table 2).
Other antigen characteristics were determined using bioinformatic tools available online (TargetP 1.1: http://
www.cbs.dtu.dk/services/TargetP/; Algpred: http://www.imtech.res.in/raghava/algpred/; Vaxijen: http://www.
ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen.html). None of the novel antigens showed allergenic potential as 
demonstrated by Algpred analysis (Table 2). Additionally, an algorithm determining whole protein antigenicity 
based on a trained alignment-independent prediction model with 70–89% accuracy was applied and results indi-
cated that all four candidates have antigenic potential (VaxiJen threshold for random prediction >0.530 (Table 2).
Epitope prediction. In addition to using an immunisation strategy based on full-length protein or anti-
genic segments, we employed a T cell epitope based strategy in order to focus immune responses on poten-
tial antigen-specific T cell epitopes. Peptides were selected on the basis of high affinity binding to MHC alleles 
expressed by BALB/c mice (MHC class I: H-2Kd and H-2Dd; MHC class II: IAd and IEd). A consensus algorithm 
approach was chosen to rank predicted peptides for all five antigens according to their scores from various predic-
tion methods (NN-align, SMM-align, combinatorial library methods) available at the Immune Epitope Database 
(IEDB, www.iedb.org)31. The predicted epitopes for each antigen (>12,000 peptides) were ranked according to 
their affinity to MHC class I (H-2Kd and H-2Dd) and class II (IAd and IEd). The top 1% predicted to bind with high 
affinity to MHC class I alleles H-2Kd and H-2Dd (1st percentile of predicted 9-mer peptides) and the top 2% pre-
dicted to bind with high affinity to MHC class II alleles IAd and IEd (2nd percentile of predicted 15-mer peptides, 
except for PY03832 which was the 1st percentile) were selected for our studies. A pool of all putative CD8+ and 
CD4+ T cell epitopes predicted for each antigen was synthesised and used to immunise mice. Additionally, a pool 
of PyCSP peptides, including both previously reported and newly predicted immunodominant CD8+ and CD4+ 
T cell epitopes (identified using our prediction algorithm) was used as a positive control.
Assessment of antigen-specific reduction in parasite burden. In order to assess the protective 
capacity of our target antigens, we determined parasite burden in the liver and in the blood after sporozoite or 
pRBC challenge. Protective capacity targeting pre-erythrocytic stages was assessed by qRT-PCR of liver-stage 
parasite burden32 as well as measurement of blood-stage parasitemia via FCAB assay33 following sporozoite chal-
lenge, in separate groups (independent experiments). To evaluate protection directed at the blood-stage of the 
parasite life cycle, immunised mice were challenged with pRBCs and blood-stage parasitemia was monitored 
via FCAB assay. Sterile protection was defined as absence of detectable blood-stage parasitemia for 30 days after 
infection, and partial protection was defined as greater than 25% reduction of parasite burden in the liver or in 
the blood as compared to non-immunised infectivity controls. A protective index was calculated as described in 
Methods (Table 3).
Individual antigens. A significant reduction in liver-stage parasite burden following sporozoite challenge 
was induced by two of the four target antigens: PY03832, 86.4% reduction (p = 0.0052) in 60% DNA/protein 
immunised mice; and PY01533, 73.5% reduction (p = 0.0044) in 80% of peptide/adjuvant immunised mice, rel-
ative to vector-only or adjuvant controls (Fig. 1A, Table 3). PY01606 (both regimens) and PY03673 (peptide/
adjuvant only) also reduced liver-stage parasite burden (37.5–77.4% reduction in 40–60% of mice) but this was 
not significant relative to controls. Immunisation with PyCSP (positive control) resulted in a significant reduction 
in liver stage parasite burden following sporozoite challenge (Fig. 1A, Table 3).
Since PY03832, PY01533, and PY01606 (but not PY03673) are expressed in the blood-stage of the parasite 
lifecycle (Table 1), we further evaluated the capacity of the target antigens to protect against blood-stage parasite 
challenge. No protection was induced by any of the novel antigens or PyCSP (Fig. 1B).
Antigen combinations. Protein microarray data22 as well as vaccine studies in humans and animal models34 
suggest that protection against the Plasmodium parasite is likely associated with a cumulative response to the 
signature antigens. Therefore, in addition to assessing the effect conferred by each antigen individually, we also 
evaluated the immunogenicity and protective capacity of different combinations of our target antigens. The two 
most protective antigens in our individual antigen studies (PY03832 and PY01533) were combined as ‘Com1/4’, 
while the other two antigens (PY01606 and PY03673) were combined as ‘Com2/3’; and all four antigens were 
combined as ‘Com1/2/3/4’.
Impressively, sterile protection was induced by DNA/protein immunisation with Com1/4 in 60% of mice, and 
Com2/3 in 30% of mice (Table 3); and by peptide/adjuvant immunisation with Com1/4 or Com1/2/3/4 in 20% 
of mice (Table 3).
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A significant reduction in liver-stage parasite burden following sporozoite challenge was induced by both 
DNA/protein and peptide/adjuvant immunisation with Com1/4 or Com1/2/3/4 (80–82% reduction in 100% 
mice, p ≤ 0.0004; and 76–87% in 100% mice, p ≤ 0.0007; respectively); and by immunisation with Com2/3 with 
the DNA/protein (74% reduction in 70% mice, p ≤ 0.0001) but not the peptide/adjuvant regimen (Fig. 2A; 
Table 3).
In independent experiments, a significant reduction of blood-stage parasite burden following sporozoite 
challenge was induced with all three combinations in 80–100% of immunised mice: Com1/4 DNA/protein or 
peptide/adjuvant, 75–84.5% reduction in 100% of mice, p ≤ 0.0001; Com2/3 DNA/protein, 64.3% reduction in 
80% of mice, p = 0.0002; and Com1/2/3/4 peptide/adjuvant, 67% reduction in 100% of mice, p = 0.0003 (Table 3; 
Fig. 2B).
In summary, we established that the P. yoelii orthologues of all four P. falciparum antigens identified by 
genome-wide antibody profiling are targets of protection against pre-erythrocytic stage malaria, as evidenced by 
significant reduction of parasite burden following sporozoite challenge, but no effect on parasitemia following 
blood stage parasite challenge. Of the four target antigens, PY03832 was the most protective, and PY03673 was 
the least protective. Notably, the combination of antigens PY03832 and PY01533, termed Com1/4, induced sterile 
protection in 60% of DNA/protein immunised mice and, in independent experiments, ~80% reduction in liver 
stage parasite burden and blood-stage parasite burden in 100% of DNA/protein or peptide/adjuvant immunised 
mice. The combination of antigens PY01606 and PY03673, termed Com2/3, induced sterile protection in 30% of 
DNA/protein immunised mice and, in independent experiments, 74% reduction in liver stage parasite burden. 
The combination of all four antigens, Com1/2/3/4, did not further enhance the protective capacity induced by 
Com1/4 or Com2/3, likely due to the reduced dose of each individual antigen in this combination (see Methods).
Monofunctional analysis of IFN-γ, IL-2 or TNF by CD4+ and CD8+ T cell responses. Next, we 
determined whether protection against sporozoite challenge was associated with the induction of Th1 type 
antigen-specific immune responses. IFN-γ has been implicated with a critical role in protective immunity 
against malaria and as a potential correlate for protection35–37. Thus, we evaluated the IFN-γ response induced by 
immunisation with our target antigens and antigen combinations via IFN-γ ELIspot and ICS, using splenocytes 
re-stimulated in vitro with A20 APC transfected with plasmid DNA or pulsed with a peptide pool representing 
the corresponding antigen. The contribution of CD8+ versus CD4+ T cells was determined by ICS, since CD8+ 
T cells are considered the most important mediator of pre-erythrocytic stage immunity35,36. In a first analysis we 
focused on the production of each cytokine individually by CD8+ or CD4+ T cell populations.
antigen/immunisation
Reduction of parasite burden in the liver Reduction of parasite burden in the blood
% sterilely protected Protection index
group protected group protected
#mice mean [%] mice [%] mean [>25%] #mice mean [%] mice [%] mean [>25%]
PY01533
DNA 10 0.5 30 54.5 5 0 20 72.3 0 30.8
peptide 5 58.8 80 73.5 5 18.2 20 30.7 0 64.9
PY01606
DNA 5 48 60 77.4 4 0 0 0 0 46.4
peptide 5 25.8 60 43.3 5 27.4 60 39.1 0 49.4
PY03673
DNA 5 0 40 43.4 5 0 0 0 0 17.4
peptide 5 26.5 60 37.5 5 0 0 0 0 22.5
PY03832
DNA 10 55.4 60 86.4 5 20 60 60 20 87.8
peptide 5 4.3 40 75.3 5 34.4 60 44.1 0 56.5
Com 1/4
DNA 15 81.9 100 81.9 10 75 100 75 60 156.9
peptide 5 79.8 100 79.8 5 84.5 100 84.5 20 164.3
Com 2/3
DNA 10 51.6 70 73.6 10 51.4 80 64.3 30 103
peptide 5 0 0 0 5 20.3 60 46.9 0 28.1
Com 1/2/3/4
DNA 5 86.7 100 86.7 5 32 60 49.6 0 116.5
peptide 5 75.6 100 75.6 5 66.9 100 66.9 20 142.5
PyCSP
DNA 15 83.4 100 83.4 15 75.9 100 75.9 50 159.3
peptide 5 60.5 80 72.2 5 64.2 100 64.2 40 121.9
vector 10 0 0 0 10 0 0 0 0 0
adjuvant 10 0 10 31 10 23.2 50 32.6 0 19.4
Table 3. Protective capacity against sporozoite challenge. Com1/4 = PY01533 + PY03832. 
Com2/3 = PY01606 + PY03673. Com1/2/3/4 = PY01533 + PY03832 + PY01606 + PY03673. #Mice: number 
of mice per group. Mean [%]: mean reduction of parasite burden across all mice tested. Mice [%]: percentage 
of mice with more than 25% reduction in parasite burden compared to infectivity controls. Mean [>25%]: 
mean reduction of parasite burden across mice with more than 25% reduction in parasite burden compared to 
infectivity controls. % sterilely protected: percentage of mice with complete absence of blood-stage parasitemia 
per group. Protection index: sum of mean reduction of parasite burden in the liver and in the blood calculated 
as the mean reduction of parasite burden for all protected mice per group (“mean-protected”) times the number 
of mice per group with more than 25% reduced parasite burden (“% mice”) compared to control group.
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In IFN-γ ELIspot, restimulated responses were generally higher using peptide/adjuvant immunisation than 
the DNA/protein regimen (Fig. 3), thereby validating the epitope prediction algorithms for the identification of 
peptide-targets of cellular immune mechanisms. The most protective antigen, PY03832, induced robust IFN-γ 
ELIspot responses that were significantly greater than controls when administered in either peptide/adjuvant or 
DNA/protein regimens (p < 0.0001) (Fig. 3). However, for the other three antigens, there was no correlation of 
protection with the number of IFN-γ spot forming cells. Consistent with the higher protective efficacy seen with 
antigen combinations compared to individual antigens, Com1/4, Com2/3 and Com1/2/3/4, all induced highly 
significant IFN-γ ELIspot responses with both immunisation regimens (p < 0.0001–0.05).
For all antigens and combinations, the ICS readout was less sensitive than ELIspot for detecting 
antigen-induced IFN-γ responses (Figs 3 and 4A). Nonetheless, ICS enabled the analysis of other core Th1 
cytokines (IL-2 and TNF) and the phenotype of cytokine secreting cells. All three antigen combinations induced 
robust IL-2 and TNF responses, as well as IFN-γ responses, with levels exceeding those induced by the indi-
vidual antigens (Fig. 4A). The effect of antigen combinations appeared to be additive when administered in a 
DNA/protein regimen and synergistic when administered in a peptide/adjuvant regimen (Fig. 4A). Notably, for 
Com1/4, there was a significant bias towards expression of Th1 cytokine responses by CD8+ T cells rather than 
CD4+ T cells (p < 0.0001) with 16.4% of the CD8+ T cells secreting IFN-γ and 33.4% of the CD8+ T cells secret-
ing TNF following Com1/4 peptide/adjuvant immunisation (Fig. 4A). In contrast, for Com2/3, peptide-induced 
IFN-γ and IL-2 were secreted almost exclusively by CD4+ T cells (each ~28% of CD4+ T cells), whereas TNF 
was secreted by both CD4+ and CD8+ T cells (59.8–63.8%) (Fig. 4A). For Com1/2/3/4, robust IL-2 and TNF 
responses of similar magnitude were contributed equally by CD8+ and CD4+ T cells (IL-2, 15–18.5%; TNF, 31.5–
38.3%; p ≤ 0.0001–0.0012)), whereas IFN-γ was significant only for the peptide/adjuvant regimen and the CD8+ 
T cell population (p < 0.0001) (Fig. 4A).
Taken together, there was no clear correlation between the frequency of immunisation-induced total Th1 
cytokine responses (including total IFN-γ responses) and protection.
Figure 1. Protective capacity of individual antigens against sporozoite challenge. Mice (n = 5–15/group 
representative of up to three independent experiments; see Table 3) were immunised with (I) plasmid DNA/
recombinant protein expressing the target antigens or (II) pools of synthetic peptides representing predicted 
CD8+ and CD4+ T cell epitopes for each antigen formulated in AbISCO100 adjuvant. Controls were immunised 
with empty vector only (I), or adjuvant only (II), or not immunised (dotted line). Mice were challenged with 
103 P. yoelii cryopreserved infectious sporozoites or 103 P. yoelii pRBC at 14 days post last immunisation. 
Protection was assessed by (A) qRT-PCR of Py18S rRNA in total liver RNA at 42 h after sporozoite challenge 
normalised against the 18S rRNA of infected but not vaccinated mice (dotted line); and (B) FCAB assay for 
days 3 to 30 after blood-stage challenge normalised against AUC of infectivity controls (dotted line). Data 
are presented as a scatter plot, with the line representing the mean and the error bars representing standard 
deviation (SD). Statistical comparison of immunised versus non-immunised infectivity controls was performed 
using one-way ANOVA followed by Bonferroni’s posthoc test, ****p < 0.0001, ***p < 0.001, **p < 0.01, 
*p < 0.05. The dotted line represents the mean value for infected but non-immunised control mice used to 
normalise vaccinated groups and for statistical analysis.
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Multifunctional T cell responses. T cells secreting more than one cytokine simultaneously (multifunc-
tional T cells) may provide optimal effector function and have higher capacity to develop into memory cells 
than single-cytokine secreting cells38. Other studies have correlated multifunctional T cells with cell-mediated 
protection against several pathogens38–42, including malaria43–45 although this is controversial46,47. Therefore, we 
next determined whether protection following antigen immunisation was associated with the induction of IFN-γ/
IL-2/TNF multifunctional T cell populations, by analysing the ICS data using a Boolean gating strategy.
Individual antigens induced robust triple, double and single positive responses when administered in a DNA/
protein regimen (Supplementary Figure S1); but, when administered in a peptide/adjuvant regimen, antigen 
restimulated IFN-γ, IL-2 or TNF T cell populations represented only a small fraction (3–10%) of the total T 
cell response for all four target antigens (Fig. 4B). The two individual antigens with the highest protective effect 
on liver-stage parasite burden, PY03832 and PY01533, both induced significant IFN-γ/IL-2/TNF triple posi-
tive CD4+ as well as CD8+ T cell responses (all p < 0.0001) (Fig. 4B, Supplementary Figure S1). Conversely, 
PY01606 and PY03673 both induced significant triple positive CD8+ but not CD4+ T cell responses (p < 0.0001 
and p = 0.0165, respectively) (Fig. 4B, Supplementary Figure S1). All four antigens individually induced signifi-
cantly higher frequencies of IFN-γ/IL-2 double positive CD8+ or CD4+ T cells (all p < 0.0001), as well as IFN-γ/
TNF CD8+ T cells (PY03832 and PY01533, p ≤ 0.002; PY01606 and PY03673, p < 0.0001) compared to controls 
(Supplementary Figure S1). Specifically, IFN-γ/TNF CD4+ T cells were induced in significant frequencies by 
the Com1/4 antigens PY0383 and PY01533 (both p < 0.0001); while TNF/IL-2 CD8+ T cells were induced in 
significant frequencies only by the Com2/3 antigens PY01606 and PY03673 (both p < 0.0001) (Supplementary 
Figure S1).
Consistent with the increase in protective efficacy, the Com1/4 combination induced very robust and highly 
significant IFN-γ/IL-2/TNF triple positive CD8+ and CD4+ T cell responses in both regimens, which were highly 
Figure 2. Protective capacity of antigen combinations against sporozoite challenge. Mice were 
immunized, challenged and protection assessed as described in the legend to Fig. 1. (A) liver-stage 
parasite burden. (B) pRBC FCAB. Com1/4 = PY01533 + PY03832; Com2/3 = PY01606 + PY03673; 
Com1/2/3/4 = PY01533 + PY03832 + PY01606 + PY03673. Data are presented as a scatter plot, with the 
line representing the mean and the error bars representing standard deviation (SD). Statistical comparison 
of immunised versus non-immunised infectivity controls was performed using one-way ANOVA followed 
by Bonferroni’s posthoc test, ****p < 0.0001, *** p < 0.001, **p < 0.01, *p < 0.05. The dotted line represents 
the mean value for infected but non-immunised control mice used to normalise vaccinated groups and for 
statistical analysis.
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synergistic compared to those of the individual antigens (Fig. 4B, Supplementary Figure S1). In contrast, Com2/3 
induced CD4+ and CD8+ T cell responses were similar to those of the individual antigens, with only modest 
CD8+ triple positive responses in either regimen (DNA: p = 0.0027; peptide: p = 0.0020) and additive effects 
only noted for IL-2 single positive CD4+ T cell populations (Supplementary Figure S1). All three combinations 
induced significant double positive CD4+ and CD8+ T cell responses with both regimens: Com1/4 and Com2/3, 
all p < 0.0001; Com1/2/3/4, all p ≤ 0.01 (Supplementary Figure S1). In marked contrast, Com1/2/3/4 showed a 
decrease in the magnitude and variety of multifunctional Th1 cytokine responses, with the triple negative fraction 
constituting ~85–95% of recall T cell responses (Fig. 4B, Supplementary Figure S1).
Notably, these data fail to show a clear correlation between the frequency of vaccine-induced multifunctional 
cytokine secreting CD8+ or CD4+ T cells and protection.
Association of protection with Th1 types cytokine expression in multifunctional T cell populations. 
Given the apparent lack of association between protection and frequency of individual cytokine responses or 
multifunctional CD4+ or CD8+ T cell populations as reported, we next explored alternative readouts. First, we 
focused on the median fluorescence intensity (MFI), where the MFI for each fluorescently labelled cytokine 
expressed by a specific cell population correlates to the amount of cytokine expressed by that specific cell popula-
tion. In general, the measured MFI for each of the three Th1 cytokines IFN-γ, IL-2 and TNF was higher in triple 
and double positive T cells than in single positive T cells, but the MFI did not correlate with protection (data not 
shown).
Next, we evaluated the integrated mean fluorescence intensity (iMFI). The iMFI is computed by multiplying 
the relative frequency (percent positive) of cells expressing a particular cytokine with the MFI of that popu-
lation. Accordingly, for both immunisation strategies, individual antigens and antigen combinations (as well 
as PyCSP control) were ranked according to protective efficacy, by reference to a protective index calculated 
based on reduction of liver-stage parasite burden and blood-stage parasitemia following sporozoite challenge 
(see Methods) (Supplementary Figure S2). Linear regression analysis (Spearman analysis) revealed a very high 
correlation between protection and the level of Th1 cytokine expression by triple positive CD8+ and CD4+ T cells 
as reflected by the integrated MFI for each cytokine (CD8+ T cells: IFN-γ: r = 0.7238, p = 0.0007; IL-2: r = 0.8147, 
p < 0.0001; TNF: r = 0.7128, p = 0.0009; CD4+ T cells: IFN-γ: r = 0.4876, p = 0.0401; IL-2: r = 0.8043, p < 0.0001; 
TNF: r = 0.7211, p = 0.0007) (Fig. 5, Table 4). Furthermore, expression of high levels of IL-2 by IL-2/TNF double 
positive CD4+ T cell populations (r = 0.5607, p = 0.0155) and high levels of TNF by IFN-γ/TNF double positive 
CD8+ (r = 0.5468, p = 0.0189) and CD4+ (r = 0.5510, p = 0.0178) T cell populations, and by IL-2/TNF double 
positive CD8+ (r = 0.6901, p = 0.0015) and CD4+ (r = 0.7727, p = 0.0002) T cell populations were also signifi-
cantly correlated with protection (Fig. 5, Table 4A).
The correlation profile with triple positive cytokine expression was very similar when considering protection 
based only on reduction of parasite burden in the liver (Table 4B), but far less pronounced when considering only 
protection against blood-stage parasitemia following sporozoite challenge (Table 4C). Here, expression of IFN-γ 
and IL-2 by IFN-γ/IL-2 double positive CD8+ (IFN-γ: r = 0.5173, p = 0.0279; IL-2: r = 0.5264, p = 0.0248) and 
CD4+ T cell populations (IL-2: r = 0.5036, p = 0.0331) was significantly correlated with protection. There was, 
Figure 3. Antigen-specific IFN-γ secreting T cell responses induced by immunisation. Splenocytes 
were harvested at 14 days post last immunisation and re-stimulated for 48 h with A20 antigen 
presenting cells transfected with antigen-encoding plasmid DNA or incubated with synthetic peptide 
pools representing each antigen. Com1/4 = PY01533 + PY03832; Com2/3 = PY01606 + PY03673; 
Com1/2/3/4 = PY01533 + PY03832 + PY01606 + PY03673. Data are presented as a box and whiskers plot, with 
the line representing the median and the whiskers illustrating the range for IFN-γ spot forming cells/million 
splenocytes (n = 5–15/group representative of up to three independent experiments) for (white bars) DNA/
protein immunisation or (black bars) peptide/adjuvant immunisation. Statistical comparison of immunised 
versus controls (either adjuvant only or empty vector only, for peptide/adjuvant or DNA/protein respectively) 
was performed using one-way ANOVA followed by Bonferroni’s posthoc test, ****p < 0.0001, ***p < 0.001, 
**p < 0.01, *p < 0.05. Statistical significance between DNA/protein and peptide/adjuvant immunisation 
regimens was determined by one-way ANOVA followed by Bonferroni’s posthoc test, ####p < 0.0001, 
###p < 0.0005, ##p < 0.005, #p < 0.05. The dotted line represents the mean background value of IFN-γ spot 
forming cells induced in adjuvant only and empty vector control groups.
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however, no correlation with expression of high levels of TNF in any double positive populations (both CD8+ 
or CD4+) (Table 4C). This is consistent with a role for the liver stage in protection against sporozoite challenge 
and for TNF early in the induction of protective immunity, while IFN-γ and IL-2 play a role later in the immune 
response.
Association of protection with secretion of specific cytokines. We also conducted a more com-
prehensive analysis of antigen-induced cytokine profiles, assaying the supernatant of splenocytes after in vitro 
re-stimulation for a panel of 10 common cytokines (IFN-γ, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p70, IL-13, IL1β, 
Figure 4. Antigen-specific and combination-specific Th1 cytokine and multifunctional T cell responses. 
Splenocytes were harvested at 14 days post last immunisation and re-stimulated for 6 h with A20 antigen 
presenting cells transfected with antigen-encoding plasmid DNA or incubated with synthetic peptide pools 
representing predicted CD8+ and CD4+ T cell epitopes for each antigen. Com1/4 = PY01533 + PY03832; 
Com2/3 = PY01606 + PY03673; Com1/2/3/4 = PY01533 + PY03832 + PY01606 + PY03673. Control = empty 
vector only or adjuvant only for DNA/protein or peptide/adjuvant groups respectively. Multi-parameter 
flow cytometry was used to quantify (A) total frequency of IFN-γ, IL-2 or TNF secreting CD4+ or CD8+ T 
cell populations analysed for each cytokine individually (i.e., total IFN-γ = cells producing only IFN-γ, or 
IFN-γ + IL-2, or IFN-γ + IL-2 + TNF; etc.) after (I) DNA/protein immunisation or (II) peptide/adjuvant 
immunisation. (B) Fraction of the total response represented by each of the eight possible combinations of 
IFN-γ, IL-2, or TNF cytokine secreting populations (triple positive, red; double positive, purple; single positive, 
orange; cytokine negative, grey). Data were analysed using FACS-DiVa software and the FlowJo population 
comparison tool and are presented as mean frequency (n = 5–15 mice pooled from up to 3 independent 
experiments) for each population after correction for background cytokine production in mock-stimulated 
cells. Error bars represent standard deviation (SD). Statistical comparison of immunised versus controls was 
performed using one-way ANOVA followed by Bonferroni’s posthoc test, ****p < 0.0001, ***p < 0.001, 
**p < 0.01, *p < 0.05.
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TNF) using a cytokine bead array. As for iMFI values, CBA data was ranked according to the protective capacity 
of each individual antigen or antigen combination for both immunisation regimens.
Consistent with IFN-γ ELISpot and ICS responses, IFN-γ (r = 0.6088; p = 0.0073) and TNF (r = 0.5119, 
p = 0.0251) responses were enhanced in protective compared to non-protective groups (Supplementary 
Figure S3). Furthermore, protection was also significantly correlated with induction of IL-1β (r = 0.4760, 
p = 0.0459) and, especially for the Com2/3 vaccines, IL-6 (r = 0.6034, p = 0.0117) (Supplementary Figure S3).
Parasite-specific antibody responses. Since all four target antigens, PY03832, PY01533, PY01606 and 
PY03673, were identified in protein microarray studies via parasite-induced antibody reactivity, we anticipated 
that antibody responses against the parasite would be induced by immunisation with these antigens. Accordingly, 
we determined the total IgG response against blood-stage parasite extract induced by immunisation with the 
target antigens in order to evaluate the relative contribution to protection of antibody compared to cellular 
responses.
At the time of parasite challenge, robust antibody responses relative to controls could be detected only for 
PY03673 peptide/adjuvant (p = 0.0098) (Supplementary Figure S4). Thus, overall, there was no apparent associ-
ation of antibody responses with protection against sporozoite or blood-stage parasite challenge (Supplementary 
Figure S4). This is consistent with a prominent involvement of cellular immune responses in the protection 
induced by immunisation with our novel antigens, rather than humoral responses. We cannot, however, exclude 
a potential role for antibodies to PY01606 and PY03673 in the partial protection observed after vaccination with 
these antigens or their combinations, since DNA/protein immunisation with these antigens and both combina-
tions containing these antigens (Com2/3 and Com1/2/3/4) could prime for boosting of antibody responses by 
parasite challenge (Supplementary Figure S4). There was no apparent priming by antigens PY03832 or PY01533.
Immunodominant epitopes after immunisation with Com1/4. The robust IFN-γ responses 
induced in our studies (as reported above) provided the opportunity to identify minimal CD4+ and CD8+ T cell 
epitopes derived from the antigens in the most promising antigen combination, Com1/4 (antigens PY01533 and 
PY03832). Indeed, we identified significant IFN-γ SFC responses to a number of predicted CD8+ T cell and CD4+ 
T cell epitopes derived from both PY01533 and PY03832, with a CD8+ T cell bias (Supplementary Figure S5).
For PY01533, the IFN-γ response induced by peptide immunisation was broadly distributed with the 
sum of responses to all of the epitopes (417 SFC/m) approximating that of the pooled peptide responses (626 
SFC/m); the most robust responses were directed against two class II restricted peptides (H-2 IAd peptide 
PY01533 II-3, LMKKCTVKTGVPVQP; IAd percentile 0.65%; 209 SFC/m; and H-2 IEd peptide PY01533 II-9, 
RRKLLYSLLRCKEGV; IEd percentile 1.62%; 235 SFC7m). In contrast, the IFN-γ response induced by immu-
nisation with PY01533 DNA/protein was directed predominantly against a single CD8+ T cell epitope (H-2 Dd 
peptide PY01533 I-14, sequence GDTRLLPIF; Dd percentile 0.70%; 205 SFC/m).
For PY03832 a dominance hierarchy was noted within the broad epitope-specific IFN-γ responses induced 
by peptide immunisation. Here, IFN-γ responses were predominantly directed against two PY03832 peptide 
epitopes (H-2 IEd peptide PY03832 II-6, sequence YWYKYVYLKKIKKKK; IEd percentile 0.04%; 746 SFC/m; 
and H-2 IEd peptide PY03832 II-9, CIDDLYWYKYVYLKK; IEd percentile 0.37%; 671 SFC/m); responses to 
each of these two epitopes were of a similar magnitude to that of the complete peptide pool (626 SFC/m) fol-
lowing peptide/adjuvant immunisation (Supplementary Figure S5). These two peptides share a 10-mer peptide 
core (YWYKYVYLKK) indicating that this 10-mer peptide may represent a minimal epitope targeted by the 
Figure 5. Association of vaccine-induced protective capacity and Th1 cytokine production. The protective 
capacity of each test group was calculated by determining the mean of the reduction of parasite burden in 
the liver and in the blood in reference to non-immunised infectivity controls as presented in Table 3, Fig. 1 
panel A. The integrated median fluorescence intensity (iMFI) for each multifunctional CD8+ or CD4+ T cell 
population (IFN-γ, IL-2 and TNF triple positive, double positive, single positive) was calculated by multiplying 
the frequency of cells producing a given cytokine combination by the magnitude of the cytokine response 
(measured as median fluorescence intensity, MFI). Correlation was determined by linear regression analysis 
using non-parametric Spearman analysis. Data of significantly correlated populations (p < 0.05; see Table 4) are 
ranked according to the protective capacity (see protective index in Table 3) (top: highest protection, bottom: 
lowest protection).
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antigen-specific IFN-γ responses; indeed, although not selected within the top 1% threshold for study here, this 
peptide was predicted to bind with high affinity to class I MHC with a H-2 Kb score of 6.5.
Another epitope derived from PY03832 (H-2Kd peptide PY03832 I-8: VYLKNTNFL; Kd percentile 0.33%; 
199 SFC/m) was recognised following DNA/protein immunisation, with a 4-fold higher number of IFN-γ SFC 
compared to controls and a 2.6-fold higher number of IFN-γ SFC compared to the complete peptide pool, 
suggesting that the entire IFN-γ response induced by protein immunisation was directed against this epitope 
(Supplementary Figure S5).
Discussion
It is widely considered that a highly effective malaria vaccine will need to include multiple antigens, likely 
from multiple stages of the complex Plasmodium parasite life cycle, including novel antigens identified from 
the parasite genomic sequence17,48. Herein, we evaluated four previously uncharacterized P. falciparum pro-
teins identified from antibody-based genome-wide screening platforms as potential pre-erythrocytic malaria 
vaccines candidates. Three of these proteins (P. falciparum PFL1620 = P. yoelii PY03832; MALP1.22 = PY01533; 
PF10925w = PY01606) were identified in the signature of 16 P. falciparum antigens associated with protective 
immunity induced by experimental immunisation with P. falciparum radiation attenuated sporozoites (RAS) as 
well as in the signature of 46 P. falciparum antigens associated with naturally acquired immunity)19,22. The fourth 
antigen (PF14_0051 = PY03673) ranked very high in the RAS signature list and was moderately reactive with 
antibodies in various naturally exposed populations in other protein microarray studies22. Our studies establish 
that all four proteins identified via antibody-based screening are targets of cell mediated immune responses and 
A CD8 CD4
IFN-γ +++ ++− +−+ +−− +++ ++− +−+ +−−
Spearman r 0.7238 0.3934 0.4200 0.2118 0.4876 0.0816 0.2669 -0.1 059
P value (two-tailed) 0.0007 0.1063 0.0827 0.3988 0.0401 0.7476 0.2844 0.6759
IL-2 +++ ++− −++ −+− +++ ++− −++ −+−
Spearman r 0.8147 0.3955 0.3913 0.0444 0.8043 0.4471 0.5607 0.0898
P value (two-tailed) <0.0001 0.1043 0.1083 0.8611 <0.0001 0.0629 0.0155 0.7230
TNF +++ +−+ −++ −−+ +++ +−+ −++ −−+
Spearman r 0.7128 0.5468 0.6901 0.4142 0.7211 0.5510 0.7727 0.4536
P value (two-tailed) 0.0009 0.0189 0.0015 0.0875 0.0007 0.0178 0.0002 0.0587
B CD8 CD4
IFN-γ +++ ++− +−+ +−− +++ ++− +−+ +−−
Spearman r 0.5625 0.3042 0.3319 0.1947 0.4295 -0.0150 0.2138 -0.1698
P value (two-tailed) 0.0151 0.2197 0.1785 0.4388 0.0753 0.9530 0.3943 0.5006
IL-2 +++ ++− −++ −+− +++ ++− −++ −+−
Spearman r 0.8125 0.3115 0.2815 0.0005 0.8208 0.3333 0.5439 -0.0418
P value (two-tailed) <0.0001 0.2083 0.2578 0.9984 <0.0001 0.1765 0.0196 0.8691
TNF +++ +−+ −++ −−+ +++ +−+ −++ −−+
Spearman r 0.7054 0.5524 0.6362 0.2193 0.7426 0.5673 0.7302 0.3746
P value (two-tailed) 0.0011 0.0174 0.0045 0.3820 0.0004 0.0141 0.0006 0.1257
C CD8 CD4
IFN-γ +++ ++− +−+ +−− +++ ++− +−+ +−−
Spearman r 0.7408 0.5173 0.2930 0.2909 0.5931 0.4242 0.3120 0.2007
P value (two-tailed) 0.0004 0.0279 0.2380 0.2416 0.0095 0.0793 0.2076 0.4245
IL-2 +++ ++− −++ −+− +++ ++− −++ −+−
Spearman r 0.6091 0.5264 0.4623 0.2307 0.5773 0.5036 0.5284 0.3435
P value (two-tailed) 0.0073 0.0248 0.0534 0.3570 0.0121 0.0331 0.0242 0.1628
TNF +++ +−+ −++ −−+ +++ +−+ −++ −−+
Spearman r 0.4099 0.1982 0.3333 0.2969 0.4630 0.2868 0.5010 0.2496
P value (two-tailed) 0.0911 0.4304 0.1765 0.2315 0.0530 0.2485 0.0342 0.3178
Table 4. Spearman correlation analysis. +++: IFN-γ/IL-2/TNF triple positive; ++−: IFN-γ/IL-2 double 
positive; +−+: IFN-γ/TNF double positive; −++: IL-2/TNF double positive; +−−: IFN-γ single positive; 
−+−: IL-2 single positive; −−+: TNF single positive. A: Protective index = sum of reduction of parasite 
burden in the liver and in the blood for each immunisation calculated as the mean reduction of parasite burden 
for all protected mice per group times the percentage of protected mice per group (protection ≥25% reduced 
parasite burden compared to control group) (see Table 3). B: Protective capacity calculated as mean reduction 
of parasite burden in the liver for all protected mice times the percentage of protected mice/group (protection 
≥25% reduced parasite burden compared to control group). C: Protective capacity calculated as mean reduction 
of parasite burden in the blood for all protected mice times the percentage of protected mice/group (protection 
≥25% reduced parasite burden compared to control group).
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protection targeting the pre-erythrocytic stage of the Plasmodium parasite. In particular, a 74–86% reduction in 
liver-stage parasite burden following sporozoite challenge was induced in 60–80% of mice immunised with anti-
gens PY03832 and PY01533, and the combination of those antigens (Com1/4) resulted in a synergistic increase in 
the protective capacity in both DNA/protein and peptide/adjuvant formulations with sterile protection in 60% of 
immunised mice. A synergistic effect on protection was also observed upon immunisation with the combination 
of PY01606 and PY03673 (Com2/3) when administered as DNA/protein but not peptide/adjuvant. These data 
establish each of our four target antigens as promising candidates for malaria vaccine development.
The increase in protective capacity of multi-antigen combinations confirms our previous findings from pro-
tein microarray studies suggesting that cumulative reactivity against multiple antigens is more strongly asso-
ciated with protection than reactivity to individual antigens22. This reinforces the concept that multiplicity of 
parasite targets would overcome genetic restriction, low immunological responsiveness and parasite evasion 
of the immune response48. Studies in rodent challenge models have established proof-of-concept for this, with 
protection demonstrated following bivalent immunisation with PyCSP plus PyHEP17 that was not induced 
with the individual antigens34 and subsequently with combinations of recently identified antigens (PY03424, 
PY0311, PY0366149; or recently identified antigens (SLAPR/SAP1 or LISP1) when combined with CSP50; or 
a previously identified antigen (TRAP) when combined with CSP51. Another study showed that viral vectors 
expressing a newly identified P. falciparum antigen PfLSP2 (as well as a previously identified vaccine candidate 
antigen PfLSA1) induced sterile protection against transgenic P. berghei sporozoite challenge in mice which was 
dependent on CD8+ T cells52.
A growing body of data now exists in humans on multi-antigen combinations of blood-stage antigens53,54 
as well as antigens expressed across several stages of the parasite lifecycle55,56. Importantly, one study in 
malaria-naïve humans showed an unprecedented level of sterile immunity (27%; 4/15 subjects) against P. falci-
parum sporozoite challenge following immunization with a combination of adenovirus-based subunit vaccines 
encoding CSP and AMA157; protection was associated with cellular immune responses. A more recent study 
combining recombinant adenovirus/poxvirus expressing TRAP with the CSP-based RTS,S/AS01B protein vac-
cine resulted in minimal enhancement of efficacy with 82.4% (14/17) of malaria-naive adults protected by immu-
nization with adenovirus/poxvirus TRAP plus RTS,S/versus 75% (12/16) immunized with RTS,S/AS01B alone58 
emphasizing the importance of both antigen and delivery method.
Findings of synergy with DNA vectors encoding PY03832 and PY01533, and PY01606 and PY03673, show 
that correct antigen selection is important in antigen combinations. The protective capacity of Com1/4 and 
Com2/3 formulations in reducing blood stage parasite burden was not further increased when all four antigens 
were combined (Com1/2/3/4), even though this combination showed a high reduction in liver stage parasite 
burden. Notably, Com1/2/3/4 induced lower frequencies of multi-functional T cell responses compared to more 
protective formulations, which further highlights the complexity of cellular immune responses required for pro-
tection. The observed reduced protective capacity and cellular immune response of Com1/2/3/4 may be due to 
the reduced dose of each antigen in the four-antigen combination, consistent with a dose-dependent protec-
tive effect, or may be explained by antigenic competition, with antigen-derived peptide epitopes competing for 
the same binding site on MHC molecules59. The potential issue of antigenic competition with multi-component 
DNA, poxvirus adenovirus and/or protein based malaria vaccines has been reported previously in murine and 
nonhuman primate studies, showing both inhibition and lack of inhibition of antigen-specific immune responses 
or protective efficacy60–66. Thus, immune interference associated with multi-antigen mixtures is complex and may 
be antigen-dependent67.
Our earlier protein microarray studies showed a lack of correlation between the magnitude of antibody 
response (serodominance) and protection, suggesting that antigens recognised by antibodies and associated with 
protection are likely to be also recognised by T cells22. We here confirm that antigens identified in a serological 
screen are targets of cellular immunity. All four target antigens induced robust CD4+ and CD8+ T cell responses. 
The two most promising vaccine antigens, PY01533 and PY03832, induced high levels of IFN-γ, IL-2 and TNF 
expressing CD4+ and CD8+ T cells, as well as IFN-γ/IL-2/TNF triple positive CD4+ and IFN-γ/TNF double 
positive CD4+ T cell populations. The increased protective capacity of the combination of these two antigens 
(Com1/4) compared to single antigen vaccination was accompanied by a synergistic increase in IFN-γ/IL-2/
TNF triple positive CD8+ T cell populations expressing higher levels of IFN-γ, IL-2 and TNF than the indi-
vidual antigens alone. Interestingly, with Com1/4 immunisation, secretion of Th1 type cytokines was strongly 
biased towards CD8+ T cells whereas the less protective combination Com2/3 had a CD4+ T cell bias. Moreover, 
although the level of pre-erythrocytic stage protection induced by immunisation with Com1/4 was not mark-
edly higher than that induced by the leading malaria vaccine target CSP, Com1/4 induced a higher frequency 
of IFN-γ expressing CD8+ and CD4+ T cells, as well as triple positive and double positive cytokine secreting 
T cells, whereas CSP induced a much more robust sporozoite-targeted antibody response. Considering their 
predicted function, our novel pre-erythrocyte antigens are unlikely to be expressed on the parasite surface or 
secreted by sporozoites, but might be presented on the surface of infected hepatocytes in the context of MHC 
molecules. Thus, we propose that antibodies targeting sporozoite entry are not involved in mediating protection, 
but antibodies targeting late liver-stage parasites or blood-stage parasites might contribute to the observed reduc-
tion in blood-stage parasitemia. Notably, there was only very limited antibody reactivity before or after parasite 
challenge with blood-stage parasite extract, suggesting that the observed reduction in blood-stage parasitemia 
was due to reduced liver-stage parasite burden. This suggests a different mechanisms of protection compared 
to CSP, and is consistent with clinical studies of the CSP-based malaria vaccine RTS,S/AS01, where the pre-
dominant mechanism of protection is considered to be sporozoite-targeted antibodies and not antigen-specific 
CD8+ T cells68. Vaccination with RTS,S induces high levels of antibodies and CD4+ T cells specific for CSP; and 
protection against malaria has been associated with antibodies especially to the repeat region in RTS,S69,70 with 
a significant synergistic interaction identified between CSP-specific CD4+ T cells and anti-CSP antibodies in 
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determining protection against clinical malaria71. There is no evidence that RTS,S induces CSP-reactive CD8+ T 
cell responses71–73.
The findings of our study support the increasing consensus among immunologists that simple measurements 
of the magnitude of immune responses are insufficient to predict immune protection. Rather phenotypical char-
acterisation of T cell responses associated with multiple effector cytokines may provide key information with 
regard to the immune control74,75. The induction and maintenance of multifunctional, virus-specific CD8+ T cells 
has been associated with control of virus infections including EBV, CMV, influenza, and non-progressive HIV-
176–78. Furthermore, studies in mice have shown that vaccine-induced multifunctional CD4+ T cell populations 
which produce more cytokine on a per-cell basis than monofunctional cells, and thus have more potent effector 
capability, correlate with protection against Leishmania major challenge38. Herein, we demonstrate that protec-
tion against Plasmodium sporozoite challenge is highly correlated with the induction of multifunctional T cell 
response. Other studies in rodent and non-human primate models of malaria have associated IFN-γ production 
in CD8+ T cells, but not multifunctional T cell responses, with protection46,47. However, our data are consistent 
with a report showing a significant increase in the proportion of CD62L− CD45RO+ effector memory T cells 
producing multiple cytokines (IFN-γ, TNF and IL-2), but not individual cytokines, in humans protected against 
sporozoite challenge by experimental infection with P. falciparum sporozoites under chloroquine chemoprophy-
laxis, at time of challenge as compared with baseline43. Also, in a phase 2a RTS,S/AS malaria vaccine study in 
malaria-naïve volunteers, there was a strong association between the titers of CSP-specific antibodies and the 
frequency of CSP peptide-reactive CD4+ T cells in the same individual, and the frequencies of CD4+ T cells 
secreting either or both IL-2 and TNF-α (but not IFN-γ) were higher in protected than non-protected subjects44.
In summary, in this report we describe the first validation for any pathogen of novel antigens identified in pro-
tein microarray studies as targets of cellular immune responses and sterilising infection-blocking protection. In 
particular, antigens PY01533 and PY03832 and that two-antigen combination (Com1/4) proved highly protective 
when administered in either DNA/protein or peptide/adjuvant regimens. Importantly, this is the first report cor-
relating protection against virulent Plasmodium parasite challenge with high-level cytokine production by mul-
tifunctional T cell populations. Our results provide experimental validation for the concept of rational vaccine 
design from genomic sequence data, demonstrate that antigens identified by serological screening are targets of 
cellular immune responses, and correlate protection against pre-erythrocytic stage malaria with multifunctional 
Th1 cytokine secreting cells and not monofunctional T cells.
Methods
Mice and parasites. Specific pathogen-free female BALB/c mice (Animal Resource Centre, Perth, Australia) 
were immunised at 6 weeks of age. The parasite strain used in all experiments was Plasmodium yoelii 17XNL. 
Cryopreserved sporozoites kindly provided by Dr. Stephen Hoffman (Sanaria Inc., Rockville, MD, USA) were 
used for sporozoite challenge. Parasitised red blood cells (pRBC) used for blood-stage challenge were obtained 
after one passage of frozen pRBC stock (derived from cryopreserved sporozoites at 14 days post infection) 
through a BALB/c mouse. All studies were approved by the QIMR Animal Ethics Committee and were conducted 
in accordance with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes 
(2004).
Parasite extract. P. yoelii extract was generated from P. yoelii 17XNL grown in BALB/c mice to approxi-
mately 50% parasitemia, as previously described79. Briefly, blood was collected by cardiac puncture, diluted with 
10 volumes of FCAB buffer (1x PBS, 0.5% FCS, 2 mM EDTA), and centrifuged at 600 rcf for 10 min. The cell pellet 
was resuspended in 0.5% w/v saponin (Sigma-Aldrich, Castle Hill, NSW) in FCAB buffer and incubated for 
30 min at 37 °C. The sample was then twice drawn through a 30-gauge needle, washed with 20 volumes of Milli-Q 
H20 and centrifuged as above. pRBC were fixed in FCAB fixation and lysis buffer (1x PBS, 4% w/v paraformalde-
hyde and 0.0067% w/v saponin) for 10 min at 37 °C. The extract was resuspended in FCAB buffer and stored at 
−80 °C prior to use. All buffers were sterile filtered (0.2 µm) immediately before use.
Synthetic peptides. Putative CD4+ and CD8+ T cell epitopes were predicted from the translated full-length 
genes of the P. yoelii orthologues of the four target proteins (PY01533, PY01606, PY03673, PY03832) (Table 1) 
and PyCSP (www.PlasmoDB.org 80,81 using computerised MHC-binding prediction algorithms available from the 
Immune Epitope Data Base (www.iedb.org)82. Peptides were synthesised by Mimotopes Pty Ltd (Clayton, VIC) 
at a purity of >80% and resuspended in 100% dimethyl sulfoxide (DMSO) and stored at −80 °C prior to use. For 
each antigen, a pool of all putative CD8+ and CD4+ T cell epitopes was used to immunise mice.
Generation of plasmid vectors for DNA vaccination and recombinant protein production 
expression. P. yoelii 17XNL genomic DNA was extracted from pRBC of BALB/c mice 14 days after infection 
with P. yoelii 17XNL sporozoites. Full-length gene sequence of the P. yoelii orthologues of each target antigen 
(PY01533, PY01606) or a partial length sequence corresponding to the protein fragment highly immunoreactive 
in protein microarray screening platforms (PY03673, PY03832)22 (www.PlasmoDB.org) were amplified by PCR. 
Gene-specific oligonucleotide primers flanked with restriction enzyme sites or sequence overhangs for DNA 
fusion were designed using Amplify 3.1 (http://engels.genetics.wisc.edu/amplify/) and Oligo Calc (www.basic.
northwestern.edu/biotools/oligocalc.html) software tools and were commercially synthesised by Sigma-Aldrich 
(Castle Hill, NSW) or Geneworks (Hindmarsh, SA).
The antigenic sequence for PY03673 includes exons 2 and 4 that were fused using an enzymatic DNA assem-
bly method as previously described83. Briefly, each exon was amplified with a 40 bp overhang complementary 
to the other exon. The resulting DNA fragments were combined in one reaction with Exonuclease III (ExoIII), 
heat-stable taq DNA ligase and Phusion® High Fidelity DNA polymerase (all from New England Biolabs, Ipswich, 
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MA) in CBAR buffer (150 mM Tris-HCl pH7.5, 10 mM MgCl2, 10 mM DTT, 800 µM dNTPs, 1 mM NAD, 5% 
PEG-800). The enzymatic assembly reaction was incubated at 37 °C for 5 min for optimal 3′ exonuclease activity, 
then at 72 °C for 20 min to stop digestion of DNA by ExoIII; then the temperature was reduced by 0.1 °C/second 
to 60 °C and then held at 60 °C for 1 h (optimal temperature for DNA polymerase and DNA ligase) to complete 
ligation and DNA repair.
PY03832 is a 10 kb long gene, so the P. yoelii sequence corresponding to the antigenic fragment of PFL1620w, 
exon 1 segment 322 was selected to represent PY03832 for our DNA/protein immunisation studies (peptide 
epitopes were predicted from the full-length sequence). Gene sequences of P. falciparum PFL1620w and its P. 
yoelii PY03832 orthologues were aligned using ClustalW2 (www.ebi.ac.uk/Tools/msa/clustalw2/) and BLASTnt 
(blast.ncbi.nlm.nih.gov/Blast.sgi) and the genetic P. yoelii fragment corresponding to PFL1620w exon 1 segment 
3 was identified.
Amplification of each target gene from P. yoelii genomic DNA was conducted in a 50-μl PCR reaction contain-
ing 1 unit/μl KOD Hot Start DNA polymerase in corresponding buffer (Novagen, San Diego, CA), 0.4 μM dNTPs, 
333 nM of each primer and 100 ng DNA template. PCR conditions were: initial denaturation at 95 °C for 2 min; 
30 cycles at 95 °C for 30 sec, 50 °C for 45 sec and 68 °C for 1 min/kb; and a final extension at 68 °C for 10 min. The 
PCR products were purified using the QIAquick PCR purification kit (Qiagen, Germany), and digested overnight 
at 37 °C using the restrictions enzymes whose recognition site was inserted into the primer sequences.
Genes were then cloned into pVR1020 (Vical, Inc., San Diego, California)84 using standard methods. The 
resulting plasmid was amplified in E. coli DH5α for DNA vaccination and purified using an endotoxin-free plas-
mid extraction kit (EndoFree Plasmid Giga Kit, Qiagen Pty Ltd, Chadstone Centre, VIC).
For protein expression, a custom pIVEX-HIS/HA vector was created by modifying the pIVEX-HIS 3.2 vec-
tor (Roche Applied Science, Castle Hill, NSW) to express a C-terminal HA tag in addition to the N-terminal 
HIS tag85. The cell-free protein expression system RTS 500 HY E. coli (5 Prime GmbH, Hamburg, Germany) 
was used to produce recombinant protein, according to manufacturer’s instructions. Recombinantly expressed 
proteins were HIS purified using Cobalt Talon Resin (Clontech Laboratories, Inc., Mountain View, CA). Briefly, 
Talon resin was equilibrated with wash buffer (20 mM sodium phosphate, 500 mM NaCl, 10 mM Imidazole) and 
incubated for 30 min at 4 °C with the RTS product solution in wash buffer containing 8 M urea. The mixture was 
then transferred to an Econo-Pac chromatography column (Bio-Rad Laboratories Pty. Ltd., Gladesville, NSW), 
the endotoxin was removed with wash buffer containing 0.05% Triton X-114, and the purified protein eluted 
with 150 mM Imidazole. To exchange the elution buffer with PBS, the protein eluate was loaded onto a 4 ml 3 K 
Amicon Ultra Filtration tube (Merck Millipore, Billerica, MA) and concentrated in three alternating spinning 
and washing steps. The protein concentration after the final centrifugation step was measured using a Nanodrop 
Spectrometer (Thermo Fisher Scientific) with an A260/A280nm ratio below 1.8 considered indicative of pure 
protein. The endotoxin level of purified protein products was assessed by endpoint chromogenic LAL assay 
(QCL-1000, Lonza Group, Ltd., Basel, Switzerland) according to manufacturer’s instructions and ranged between 
0.5–0.9 EU/ml. Protein quality after cell-free expression was also evaluated by SDS-PAGE and western blot, using 
the N-terminal HIS tag to detect recombinant protein. As expected, full-length as well as partial length protein of 
varying sizes was produced in the cell-free system (Supplementary Figure S6), covering all possible epitopes and 
effectively boosting DNA primed responses.
Immunisation and Challenge. BALB/c mice (n = 5/group) were immunised in independent experiments 
at three weekly intervals with either individual antigens or antigen combinations, in both DNA prime/protein 
boost and peptide/adjuvant immunisation regimens. For the DNA/protein regimen, mice were immunised with 
two intramuscular doses (tibialis anterior muscle; dose split between two legs) of 100 µg plasmid DNA followed 
by one intraperitoneal dose of 10 µg recombinant protein formulated 50:50 in Alhydrogel® (Alum; Brenntag 
Biosector, Denmark). For the peptide/adjuvant regimen, mice were immunised with three subcutaneous doses of 
pooled synthetic peptides (29.5 µg/peptide, 10% DMSO) formulated with 12 µg AbISCO100 (Isconova, Sweden). 
The same total dose of DNA, protein or peptide was used for immunisations with individual antigens and the 
antigen combinations, so the amount of individual antigens in combinations was reduced accordingly. Mice 
administered empty pVR1020 prime followed by a 50:50 Alum/1x PBS boost were used as the control group for 
DNA/protein studies (vector control), and mice administered AbISCO100 adjuvant only were used as the control 
group for peptide/adjuvant studies (adjuvant control).
Two weeks after the last immunisation, mice were challenged with either 1000 cryopreserved sporozoites in 
1% mouse sera or 1000 pRBC in PBS, in a volume of 200 µl intravenously in the tail vein. The sporozoite dose was 
based on counts conducted before freezing; we routinely use cryopreserved sporozoite stocks for in vivo challenge 
experiments32,33,79 and have established that 100% of mice inoculated with as few as 50 cryopreserved P. yoelii 
sporozoites developed blood-stage parasitemia79. Infectivity controls (non-immunised naïve mice challenged 
with parasites in parallel to the test groups) were included in all experiments, and all developed blood-stage 
parasitemia from day 4 post sporozoite challenge (data not presented). The well characterized antigen, P. yoelii 
circumsporozoite protein (PyCSP) administered in parallel to the test groups served as a positive control for all 
immunogenicity and protection studies.
Assessment of liver-stage parasite burden via quantitative RT-PCR. Livers were harvested 42 h 
after sporozoite challenge and liver-stage parasite burden quantitated by qRT-PCR as previously described32,79. 
P. yoelii 18 S rRNA (Py18S) and mouse GAPDH were quantified using a standard curve of cloned cDNA and 
the ratio of Py18S cDNA to total mouse cDNA (GAPDH) was calculated and normalised against the infectivity 
control group to give the percent reduction of liver parasite burden (Microsoft Excel 2007, version 12, Microsoft 
Corporation, WA, USA).
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Assessment of blood-stage parasitemia via flow cytometric assessment of blood (FCAB 
assay). The kinetics and burden of blood-stage infection were monitored daily from day 3 to day 14 and 3 
times a week from day 14 to day 30 after either sporozoite or pRBC challenge, by flow cytometric assessment of the 
blood (FCAB) as described previously32,33. The percentage of fluorescent cells was measured by flow-cytometry 
on an HTS-equipped FACSCanto II (BD Biosciences, San Jose, CA) and data were analysed using FlowJo software 
version 9.1 (Treestar Inc., Ashland, OR, USA). The percentage of pRBCs was measured at multiple time points 
over the course of infection and the Area Under the Curve (AUC) of blood-stage parasitemia over time was cal-
culated for immunised and control groups. In order to compare different experiments, AUC values of immunised 
mice were normalised to AUC values of infectivity control mice.
A value expressing the protective capacity for each antigen/vaccine combination was calculated for immu-
nised mice and control groups by multiplying the average reduction of parasite burden in the liver (% determined 
by qRT-PCR) and the average reduction of blood-stage parasitemia (% determined by FCAB) with the number of 
protected mice (protection defined as >25% reduction of parasite burden compared to infectivity controls) and 
calculating the sum of liver-stage and blood-stage protective index:
(average reduction of liver-stage parasite burden in protected mice [%] × number of protected mice/
group) + (average reduction of blood-stage parasitemia [%] × number of protected mice/group).
Immunogenicity assays. Spleens of vaccinated and unvaccinated mice were harvested at the time of 
challenge (12 days after the third immunisation) and re-stimulated with A20 (mouse B lymphocyte cell line, 
ATCC # TIB-208) antigen presenting cells transfected with the corresponding plasmid DNA or pulsed with 
the corresponding peptide pool. Briefly, A20 cells were transfected with antigen-encoding plasmid DNA (5 µg 
DNA/5 × 106 cells) using the AMAXA Nucleofector system (kit V, program L-13; Lonza Group, Ltd., Basel, 
Switzerland) according to manufacturer’s instructions, or pre-incubated with 5 µg/ml peptide pool, and then 
irradiated with approximately 16666 cGy (Cs137 irradiator). Then, 5 × 105 splenocytes/well were co-incubated 
with 1.5 × 105 antigen-presenting A20 cells/well at 37 °C for 6–48 hr depending on the assay.
IFN-γ ELISpot assay. IFN-γ secretion was assayed by ELISpot as previously described79, using 5 × 105 sple-
nocytes/well and 1.5 × 105 peptide-pulsed or antigen-transfected A20 APCs/well in triplicate (for individual 
mice) and a 42 hr incubation period. Spot forming cells (SFCs) were counted using the AID ELISpot reader (AID 
ELISpot reader classic, AID, San Diego, CA).
Cytometric Bead Array (CBA). A comprehensive panel of Th1 and Th2 cytokines (IL-1β, IL-2, IL-4, 
IL-5, IL-6, IL-10, IL-12, IL-13, IFN-γ, TNF) was assayed using the mouse cytometric bead array (CBA) flex 
kit (BD Biosciences, San Jose, CA) also as previously described32, with 5 × 105 splenocytes/well and 1.5 × 105 
peptide-pulsed or antigen-transfected A20 APCs/well in 96-well round-bottom plates (for individual mice) and 
a 48 hr incubation period. Fluorescence intensity of the detection beads was measured on the FACSArray (BD 
Biosciences, San Jose, CA) and data analysed using FlowJo software (FlowJo software version 9.1 Treestar Inc.).
Intracellular Cytokine Staining (ICS). The phenotype and frequency of cytokine secreting cells and 
multifunctional T cell populations was determined by Intracellular Cytokine Staining (ICS), as previously 
described79, with 5 × 105 splenocytes/well and 1.5 × 105 peptide-pulsed or antigen-transfected A20 APCs/well in 
96-well round-bottom plates and a 6 hr incubation period. Briefly, cells were stained for surface molecules CD4 
(mCD4-PerCP Cy5, Invitrogen) and CD8 (mCD8-FITC, Biolegend), fixed with 1% paraformaldehyde, and then 
stained for intracellular cytokines IFN-γ (mIFN-γ-APC, Miltenyi Biotec), IL-2 (mIL-2-PE, Biolegend), and TNF 
(mTNF-PE Cy7, eBioscience) in 1x Perm/WashTM buffer (BD Bioscience) overnight at 4 °C in the dark. Samples 
were acquired on an HTS-equipped FACS Canto II using FACS-DiVa software (BD Bioscience).
The percentage of IFN-γ, IL-2 or TNF positive CD4+ and CD8+ splenocyte populations was calculated by 
subtracting background values of mock-stimulated cells from the antigen-specific re-stimulated sample using 
Overton subtraction in the FlowJo Population Comparison tool (FlowJo software version 9.1 Treestar Inc.).
CD4+ and CD8+ T cell populations expressing one, any two, or all three cytokines simultaneously (multi-
functional) were defined using the FlowJo Boolean Gating tool (FlowJo software version 9.1 Treestar Inc.). The 
background frequencies of cytokine producing populations in mock-stimulated samples were subtracted and 
statistical analysis of data was performed using Prism version 6.00. The median fluorescence intensity (MFI) of 
the three cytokines in single, double or triple positive T cell populations relates to the amount of cytokine secreted 
from each of these populations. The integrated MFI (iMFI) was therefore calculated by multiplying the MFI for 
each individual cytokine with the relative frequency of multifunctional populations expressing that cytokine, as 
an indicator of T cell functionality.
Indirect fluorescent antibody test (IFAT). Sera of vaccinated and unvaccinated mice were collected 2 
weeks after each immunisation (after the third immunisation sera were collected 4 days before challenge) and 
21 days after challenge. Parasite specific antibody responses were assayed using a flow-based Indirect fluorescent 
antibody test (IFAT) as previously described79,86 using 30 µl of serum diluted in FCAB buffer (1/100 pre-challenge, 
1/300 post-challenge) and incubated with 10 µl of parasite extract for 20 min at RT. Antibodies binding to the P. 
yoelii parasite extract were stained with secondary goat anti-mouse IgG-DyLight 405 (Biolegend) for 15 min at 
4 °C. Samples were acquired on a HTS-equipped FACSCanto II and post-acquisition data analysis was performed 
with FlowJo (software version 9.1 Treestar Inc.). The MFI for total IgG measured in immunised mice was normal-
ised to that of infectivity controls.
Statistical Analysis. The Prism 6.0 software package (Graph-Pad, San Diego, CA) was used for statistical 
analysis. For each test group, all mice were assayed individually and geometric mean responses were calculated. 
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Results obtained after vaccination with DNA/protein formulations of PY01533, PY03832, combination 1/4 and 
combination 2/3 were confirmed in independent experiments, so the number of samples per group included in 
the data analyses varied: PyCSP and Com1/4 DNA/protein, n = 15; PY01533, PY03832 and Com2/3 DNA/pro-
tein, n = 10; PY01606, PY03673 and Com1/2/3/4 DNA/protein, n = 5; Peptide/adjuvant studies, n = 5. One-way 
ANOVA followed by Bonferroni’s correction for multiple comparisons was used to determine statistical signif-
icance between immunised and control groups. Correlation and linear regression analysis of protection with 
multifunctional T cell data was conducted using the non-parametrical Spearman analysis. Correlation and linear 
regression analysis of protection with iMFI and CBA data was conducted using the non-parametrical Spearman 
analysis (GraphPad Prism). Error bars in all figures represent standard deviation (SD).
Data Availability. The authors declare that the data supporting the findings of this study are available within 
the article and its Supplementary Information files.
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